Abstract
Commercial wearable devices are surfacing as an appealing mechanism to detect COVID-19 and potentially other public health threats, due to their widespread use. To assess the validity of wearable devices as population health screening tools, it is essential to evaluate predictive methodologies based on wearable devices by mimicking their real-world deployment. Several points must be addressed to transition from statistically significant differences between infected and uninfected cohorts to COVID-19 inferences on individuals. We demonstrate the strengths and shortcomings of existing approaches on a cohort of 32, 198 individuals who experience influenza like illness (ILI), 204 of which report testing positive for COVID-19. We show that, despite commonly made design mistakes resulting in overestimation of performance, when properly designed wearables can be effectively used as a part of the detection pipeline. For example, knowing the week of year, combined with naive randomised test set generation leads to substantial overestimation of COVID-19 classification performance at 0.73 AUROC. However, an average AUROC of only 0.55 ± 0.02 would be attainable in a simulation of real-world deployment, due to the shifting prevalence of COVID-19 and non-COVID-19 ILI to trigger further testing. In this work we show how to train a machine learning model to differentiate ILI days from healthy days, followed by a survey to differentiate COVID-19 from influenza and unspecified ILI based on symptoms. In a forthcoming week, models can expect a sensitivity of 0.50 (0-0.74, 95% CI), while utilising the wearable device to reduce the burden of surveys by 35%. The corresponding false positive rate is 0.22 (0.02-0.47, 95% CI). In the future, serious consideration must be given to the design, evaluation, and reporting of wearable device interventions if they are to be relied upon as part of frequent COVID-19 or other public health threat testing infrastructures.
Competing Interest Statement
Luca Foschini is co-founder of Evidation Health, a company that powers research studies with PGHD (Person-Generated Health Data).
Funding Statement
Funded by NIH, The National Cancer Institute (NCI) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) AWARD N. 75N91020C00034.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study is approved by Solutions IRB (Initial approval date:, COVID-19 amendment: 4/3/2020)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The completed coded curated study data can be requested by qualified researchers via the Sage Synapse platform: https://www.synapse.org/#!Synapse:syn22891469/.
